Volume 55, Issue 1 pp. 83-87
Pediatric Intervention

Cost implications of closure of atrial septal defect

Sherri S. Baker MD

Sherri S. Baker MD

Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina

Search for more papers by this author
Martin P. O'Laughlin MD

Martin P. O'Laughlin MD

Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina

In accordance with the policy of the Journal, the designated author discloses a financial or other interest in the subject discussed in this article.

Search for more papers by this author
James G. Jollis MD

James G. Jollis MD

Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina

Search for more papers by this author
J. Kevin Harrison MD

J. Kevin Harrison MD

Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina

Search for more papers by this author
Stephen P. Sanders MD

Stephen P. Sanders MD

Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina

Search for more papers by this author
Jennifer S. Li MD

Corresponding Author

Jennifer S. Li MD

Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina

Pediatric Cardiovascular Program, Duke University Medical Center, DUMC Box 3090, Durham, NC 27710Search for more papers by this author
First published: 20 December 2001
Citations: 16

Abstract

We sought to evaluate the relative cost of surgical and device closure of atrial septal defect. Device closure for atrial septal defects is becoming an alternative to surgical closure. We examined the hospital-generated cost data in 13 patients who underwent surgical repair and 15 patients who underwent device closure of an atrial septal defects (ASD) or patent foramen ovale (PFO) during a prospective clinical trial of the device. The cost of device closure of ASD was $7,837 less on average than surgical closure when the cost of the occlusion device was excluded (device closure cost $7,397 ± $2,822, surgical closure cost $15,234 ± $3,851; P < 0.001). When adjusted for a 5% failure rate of device closure, the cost savings was $7,076. Device closure of ASD results in substantial hospital-related cost savings that will be an important consideration once new devices are approved for clinical use. Cathet Cardiovasc Intervent 2002;55:83–87. © 2002 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.